CLAIMS

1. Sterilized composition, in an aqueous medium, comprising at least one hyaluronic acid and at least one water-soluble salt of sucrose octasulphate, characterized in that the said composition is a physical mixture and in that the ratio by weight of the content of hyaluronic acid [HA] to the content of water-soluble salt of sucrose octasulphate [SOS], [HA]/[SOS], is greater than or equal to 0.1.

2. Composition according to Claim 1, characterized in that, when it is analysed by proton ^{1}H NMR spectroscopy, the value of the chemical shift of the anomeric proton of the salt of sucrose octasulphate is identical to the value of the chemical shift of the anomeric proton of the salt of sucrose octasulphate alone in solution.

3. Composition according to either one of the preceding claims, characterized in that the ratio by weight of the content of hyaluronic acid [HA] to the content of water-soluble salt of sucrose octasulphate [SOS], [HA]/[SOS], is comprised between 0.1 and 5000.

4. Composition according to any one of the preceding claims, characterized in that the molecular weight Mw of the hyaluronic acid is comprised within a range from 0.01 MDa to 5 MDa.

5. Composition according to any one of the preceding claims, characterized in that the content of hyaluronic acid is comprised between 2 mg/g and 50 mg/g of composition.

6. Composition according to any one of the preceding claims, characterized in that the content of hyaluronic acid is comprised between 4 mg/g and 40 mg/g of composition.

7. Composition according to any one of the preceding claims, characterized in that it comprises at least one non-crosslinked hyaluronic acid.

8. Composition according to any one of the preceding claims, characterized in that it additionally comprises at least one crosslinked hyaluronic acid.

9. Composition according to Claim 8, characterized in that the crosslinked hyaluronic acid exhibits a degree of crosslinking X comprised between 0.001 and 0.5.

10. Composition according to any one of the preceding claims, characterized in that it comprises at least one hyaluronic acid substituted by a group contributing lipophilic or hydrating properties.

11. Composition according to any one of the preceding claims, characterized in that it additionally comprises another polysaccharide.

12. Composition according to any one of the preceding claims, characterized in that the water-soluble salt of sucrose octasulphate is chosen from the group consisting of alkali metal salts, alkaline earth metal salts, silver salts, the ammonium salts and amino acid salts.

13. Composition according to Claim 12, characterized in that the water-soluble salt of sucrose octasulphate is chosen from the group consisting of the alkali metal salts and the alkaline earth metal salts.

14. Composition according to Claim 11, characterized in that the water-soluble salt of sucrose octasulphate is the sodium salt of sucrose octasulphate or the potassium salt of sucrose octasulphate.

15. Composition according to any one of the preceding claims, characterized in that the content of water-soluble salt of sucrose octasulphate is comprised between 0.01 mg/g and 40 mg/g of composition.

16. Composition according to any one of the preceding claims, characterized in that it additionally comprises at least one active principle.

17. Composition according to Claim 16, characterized in that the active principle is chosen from antioxidants, local anaesthetics or vitamins, alone or in combination.

18. Composition according to Claim 17, characterized in that the antioxidants are chosen from polyols.

19. Composition according to Claim 17, characterized in that the local anaesthetics are chosen from the group consisting of lidocaine, procaine, mepivacaine, ropivacaine, bupivacaine and their pharmaceutically acceptable salts.

20. Composition according to Claim 16, characterized in that the content of active principle(s) is comprised between 0.01 and 10% by weight, with respect to the total weight of the composition.

21. Process for the manufacture of a composition according to Claims 1 to 19, characterized in that it comprises at least:

- a hydration step of fibres of at least one hyaluronic acid, in order to obtain a hydrogel,
- a mixing step of a solution of water-soluble salt of sucrose octasulphate with the hydrogel obtained in the preceding step,
- a homogenization step, and
- a steam autoclaving step.

22. Process for the manufacture of a composition according to Claim 20, characterized in that it additionally comprises at least one crosslinking step.

23. Use of a composition according to Claims 1 to 20 for the formulation of a viscosupplementation composition.

24. Use of a composition according to Claims 1 to 20 for the formulation of a composition as a dermal filler.

25. Use of a composition according to Claims 1 to 20 for the formulation of a composition for the treatment of ocular dryness.

26. Cosmetic formulation, characterized in that it comprises a composition according to Claims 1 to 20 and at least one cosmetically acceptable excipient.

27. Cosmetic formulation according to Claim 26, characterized in that it comprises between 0.01 and 10% by weight of the composition according

to Claims 1 to 20, with respect to the total weight of the said cosmetic formulation.

28. Kit comprising a composition according to Claims 1 to 20, packaged in sterilized syringes or in sterilized single-dose bottles.

CLAIMS

1. A sterilized composition, in an aqueous medium, comprising at least one hyaluronic acid and at least one water soluble salt of sucrose octasulphate, wherein the composition is a physical mixture, the ratio by weight of the content of hyaluronic acid [HA] to the content of water-soluble salt of sucrose octasulphate [SOS], [HA]/[SOS], ranges from 0.1 to 2500 and the molecular weight of the hyaluronic acid ranges from 0.01 MDa to 5 MDa.

2. The composition according to claim 1, wherein, when it is analyzed by proton ^{1}H NMR spectroscopy, the value of the chemical shift of the anomeric proton of the salt of sucrose octasulphate is identical to the value of the chemical shift of the anomeric proton of the salt of sucrose octasulphate alone in solution.

3. The composition according to claim 1, wherein the content of hyaluronic acid ranges from 2 mg/g to 50 mg/g of composition.

4. The composition according to claim 1, wherein the content of hyaluronic acid is ranges from 4 mg/g to 40 mg/g of composition.

5. The composition according to claim 1, wherein it comprises at least one non-crosslinked hyaluronic acid.

6. The composition according to claim 1, wherein it additionally comprises at least one crosslinked hyaluronic acid.

7. The composition according to claim 6, wherein the crosslinked hyaluronic acid exhibits a degree of crosslinking X ranges from 0.001 to 0.5.

8. The composition according to claim 1, wherein it comprises at least one hyaluronic acid substituted by a group contributing lipophilic or hydrophilic properties.

9. The composition according to claim 1, wherein it additionally comprises another polysaccharide.

10. The composition according to claim 1, wherein the water-soluble salt of sucrose octasulphate is selected from the group consisting of alkali metal salts, alkaline earth metal salts, silver salts, the ammonium salts and amino acid salts.

11. The composition according to claim 10, wherein the water-soluble salt of sucrose octasulphate is selected from the group consisting of the alkali metal salts and the alkaline earth metal salts.

12. The composition according to claim 9, wherein the water-soluble salt of sucrose octasulphate is the sodium salt of sucrose octasulphate or the potassium salt of sucrose octasulphate.

13. The composition according to claim 1, wherein the content of water-soluble salt of sucrose octasulphate ranges from 0.01 mg/g to 40 mg/g of composition.

14. The composition according to claim 1, wherein that it additionally comprises at least one active principle.

15. The composition according to claim 14, wherein the active principle is chosen from antioxidants, local anesthetics or vitamins, alone or in combination.

16. The composition according to claim 15, wherein the antioxidants are chosen from polyols.

17. The composition according to claim 15, wherein the local anesthetics are selected from the group consisting of lidocaine, procaine, mepivacaine, ropivacaine, bupivacaine and their pharmaceutically acceptable salts.

18. The composition according to claim 14, wherein the content of active principle(s) is comprised between 0.01 and 10% by weight, with respect to the total weight of the composition.

19. A process for the manufacture of a composition according to claim 1, wherein it comprises at least:

a hydration step of fibers of at least one hyaluronic acid, in order to obtain a hydrogel,

a mixing step of a solution of water-soluble salt of sucrose octasulphate with the hydrogel obtained in the preceding step,

a homogenization step, and

a steam autoclaving step.

20. A process for the manufacture of a composition according to claim 18, wherein it additionally comprises at least one crosslinking step.

21. A viscosupplementation composition comprising the composition according to claim 1.

22. A dermal filler comprising the composition according to claim 1.

23. A composition for the treatment of ocular dryness comprising the composition according to claim 1.

24. A cosmetic formulation, wherein it comprises the sterilized composition according to claim 1 and at least one cosmetically acceptable excipient.

25. The cosmetic formulation according to claim 24, wherein it comprises, from 0.01 to 10% by weight, with respect to the total weight of the cosmetic formulation, of the sterilized composition.

26. A kit comprising a composition according to claim 1, packaged in sterilized syringes or in sterilized single-dose bottles.